Analyst
Jefferies
Equibles does not estimate personal net worth.
Amy Lee is recorded as Analyst at Jefferies. Amy Lee has spoken on 5 earnings calls and 5 other investor events across 6 companies, most recently for Liquidia Corp on August 12, 2026. Those appearances were for Liquidia Corp (LQDA), Scholar Rock Holding Corp (SRRK), ELI LILLY & Co (LLY), Ironwood Pharmaceuticals Inc (IRWD), Gilead Sciences, Inc. (GILD) and 1 other company. The companies whose calls Amy Lee spoke on are classified in the Healthcare sector.
“I just wanted to start with two non-launch-related questions. The first one, on your 75-patient REWARM-Reynolds study, what efficacy signal would you need to see to move this directly into a registrational trial?”
“I just wanted to put a finer point on the second still finish facility. You mentioned that, you know, you submitted data that the FDA requested, the type C, which sounds encouraging, but could you give us a sense of what was included in that data package?”
“In your Reddit trials, there was a meaningful amount of non-completers in the placebo arm, So I was just curious on, you know, what those patients were. And do you see it being more difficult to run global controlled large-scale trials going forward?”
“I'm a biotech analyst at Jeffries, and I have the pleasure of welcoming David Halal, the CEO of Scholarock. I'll turn it over to him for some opening remarks.”
“I'm a biotech analyst at Jefferies, and I have the pleasure of welcoming the Liquidea team, Roger Jess, the Chief Executive Officer, and Mike Casita, the CFO and COO.”
Jefferies
Analyst
Transcript header (unverified)
LQDA
Drug Manufacturers - Specialty & Generic · Healthcare
LLY
Drug Manufacturers - General · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
Arcellx, Inc.
Biotechnology · Healthcare
Drug Manufacturers - General · Healthcare
Jefferies Global Healthcare Conference in London
Arcellx, Inc.
